A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Paeonia lactiflora Pall. On the Treatment of Alzheimer’s Disease

Table 2

The 33 key targets of PLP acting on AD.

Target	Name	Degree	Betweenness centrality	Closeness centrality
APP	Amyloid precursor protein	81	0.192	0.517
TP53	Tumor protein P53	54	0.096	0.507
AKT1	RAC-alpha serine/threonine-protein kinase	54	0.039	0.483
MAPK8	Mitogen-activated protein kinase 8	51	0.042	0.489
IL6	Interleukin 6	50	0.035	0.485
INS	Insulin	47	0.060	0.490
TNF	Tumor necrosis factor	46	0.022	0.473
MAPK1	Mitogen-activated protein kinase 1	45	0.036	0.481
JUN	Transcription factor AP1	44	0.026	0.482
VEGFA	Vascular endothelial growth factor A	43	0.029	0.475
APOE	Apolipoprotein E	38	0.040	0.458
IL8	Interleukin 8	38	0.028	0.444
BDNF	Brain-derived neurotrophic factor	37	0.039	0.465
CASP3	Caspase 3	35	0.023	0.461
IL1B	Interleukin-1β	35	0.016	0.443
RELA	Transcription factor p65	33	0.012	0.456
UBB	Ubiquitin B	32	0.032	0.441
HSP90A	Heat shock protein HSP 90	32	0.031	0.431
NOS3	Endothelial nitric oxide synthase	30	0.018	0.449
AGTR1	Type-1 angiotensin II receptor	29	0.016	0.437
PTGS2	Prostaglandin G/H synthase 2	29	0.026	0.435
NGF	Nerve growth factor	28	0.013	0.443
PPARG	Peroxisome proliferator activated receptor γ	28	0.013	0.434
AR	Androgen receptor	25	0.026	0.421
SP1	Sp1 transcription factor	24	0.014	0.424
CASP8	Caspase 8	22	0.007	0.436
PSEN1	Presenilin 1	22	0.015	0.427
CDK5	Cyclin-dependent kinase 5	22	0.013	0.424
NGFR	Nerve growth factor receptor	21	0.011	0.440
CAT	Catalase	21	0.020	0.423
MAPT	Microtubule associated protein tau	20	0.010	0.422
LDLR	Low-density lipoprotein receptor	20	0.020	0.417
GSK3B	Glycogen synthase kinase-3β	17	0.006	0.433